Horie, Kanta http://orcid.org/0000-0001-7736-2614
Salvadó, Gemma http://orcid.org/0000-0002-5210-9230
Barthélemy, Nicolas R.
Janelidze, Shorena http://orcid.org/0000-0003-2869-8378
Li, Yan
He, Yingxin http://orcid.org/0000-0003-2543-4553
Saef, Benjamin
Chen, Charles D.
Jiang, Hong
Strandberg, Olof
Pichet Binette, Alexa http://orcid.org/0000-0001-5218-3337
Palmqvist, Sebastian http://orcid.org/0000-0002-9267-1930
Sato, Chihiro http://orcid.org/0000-0002-7639-8727
Sachdev, Pallavi
Koyama, Akihiko
Gordon, Brian A. http://orcid.org/0000-0003-2109-2955
Benzinger, Tammie L. S. http://orcid.org/0000-0002-8114-0552
Holtzman, David M. http://orcid.org/0000-0002-3400-0856
Morris, John C.
Mattsson-Carlgren, Niklas
Stomrud, Erik
Ossenkoppele, Rik http://orcid.org/0000-0003-1584-7477
Schindler, Suzanne E. http://orcid.org/0000-0002-1680-1465
Hansson, Oskar http://orcid.org/0000-0001-8467-7286
Bateman, Randall J. http://orcid.org/0000-0002-7729-1702
Article History
Received: 2 January 2023
Accepted: 5 June 2023
First Online: 13 July 2023
Competing interests
: K.H. is an Eisai-sponsored voluntary research associate professor at Washington University and has received salary from Eisai. Washington University. R.J.B. and D.M.H. have equity ownership interest in C2N Diagnostics. R.J.B. and D.M.H. receive income from C2N Diagnostics for serving on the scientific advisory board. K.H., N.R.B., C.S. and R.J.B. may receive income based on technology (Methods to Detect MTBR-tau Isoforms and use Thereof) (PCT/US2020/046224) licensed by Washington University to C2N Diagnostics. H.J. and D.M.H. may receive income based on technology (Anti-tau MTBR Antibodies and Methods to Detect Endogenously Cleaved Fragments of Tau and uses Thereof) (USSN 63/400,345) licensed by Washington University to C2N Diagnostics. R.J.B. is an unpaid scientific advisory board member of Roche and Biogen and receives research funding from Avid Radiopharmaceuticals, Janssen, Roche/Genentech, Eli Lilly, Eisai, Biogen, AbbVie, Bristol Myers Squibb and Novartis. O.H. has acquired research support (for the institution) from ADx, Avid Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, Fujirebio, GE Healthcare, Pfizer and Roche. In the past 2 years, he has received consultancy/speaker fees from AC Immune, Amylyx, Alzpath, BioArctic, Biogen, Cerveau, Eisai, Fujirebio, Genentech, Novartis, Roche and Siemens. S.E.S. has analyzed data provided by C2N Diagnostics to Washington University, but she has not received any research funding or personal compensation from C2N Diagnostics. She has served on a scientific advisory board for Eisai. D.M.H. is on the scientific advisory board of Genentech, Denali and Cajal Neurosciences and consults for Alector. S.P. has served on scientific advisory boards and/or given lectures in symposia sponsored by BioArtic, Biogen, Cytox, Eli Lilly, Geras Solutions and Roche. The remaining authors declare no competing interests.